XML 57 R21.htm IDEA: XBRL DOCUMENT

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions In November 2018, the Company entered into a Material Transfer Agreement (“MTA”) with Leucadia Life Sciences (“Leucadia”) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for acute myeloid leukemia (“AML”). In December 2019, the MTA was amended and increased to $1,470,000 to account for additional deliverables in development of the PCR-based assay. The Company’s CEO, Dr. Thomas Adams, is a principal stockholder of Leucadia. In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, VP of Operations of Leucadia, who is the son of Dr. Adams. During the years ended December 31, 2019 and 2018, the Company incurred and recorded approximately $1,005,000 and $183,000, respectively, of research and development expenses for services performed by Leucadia and Tommy Adams.